WorldPingVaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.
Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.
When each newsroom published on this story, oldest first — all times UTC.
STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.
Read the full report at STATLiving hubs that keep updating as this story develops.
WorldPingVaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merck…
Brief by WorldPing · Original reporting by STAT
WorldPingA melanoma vaccine succeeded in a late-stage clinical trial. The question now is whether other cancer vaccines will work — and whether mRNA is up to the task.
Brief by WorldPing · Original reporting by STAT
WorldPingHow big a deal is a hit to 1% of Russia's GDP?
Brief by WorldPing · Original reporting by Fortune
WorldPingFormer MP and Greens Institute head, Max Chandler-Mather, says proposal for publicly owned supermarket chain will ease grocery prices Get our new political email , free app or daily news podcast More than 200 Coles and Woolworths supermarkets would b…
Brief by WorldPing · Original reporting by The Guardian
WorldPingThe star reveals why he is "very selective" about releasing music - and shares his future collab hopes.
Brief by WorldPing · Original reporting by BBC News
WorldPingIn traditional markets, the U.S. Dollar Index jumped to 102.53 early today, the highest since April 2025, extending its rise from the Sept. 9 low of 98.60.
Brief by WorldPing · Original reporting by CoinDesk
WorldPing